Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in
the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with
systemic scleroderma